دورية أكاديمية
أعرض في EDS

Hypertension management in chronic kidney disease: A guide for NPs.

التفاصيل البيبلوغرافية
العنوان: Hypertension management in chronic kidney disease: A guide for NPs.
المؤلفون: Liddell TS, Henry-Okafor Q, Umeukeje EM
المصدر: The Nurse practitioner [Nurse Pract] 2024 Jul 01; Vol. 49 (7), pp. 13-20. Date of Electronic Publication: 2024 Jun 25.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Springhouse Corp Country of Publication: United States NLM ID: 7603663 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8662 (Electronic) Linking ISSN: 03611817 NLM ISO Abbreviation: Nurse Pract Subsets: MEDLINE
أسماء مطبوعة: Publication: Springhouse, PA : Springhouse Corp.
Original Publication: Trenton, N. J., Medical Media Corp.
مواضيع طبية MeSH: Renal Insufficiency, Chronic*/complications , Renal Insufficiency, Chronic*/nursing , Hypertension*/nursing , Hypertension*/drug therapy , Nurse Practitioners*, Humans ; Antihypertensive Agents/therapeutic use ; Patient Education as Topic ; Practice Guidelines as Topic
مستخلص: Abstract: This article offers a guide for NPs for managing hypertension (HTN) in adults in the setting of chronic kidney disease (CKD). It outlines evidence-based strategies, including lifestyle modifications, pharmacologic interventions, and patient education measures, that can be used in patients with CKD to optimize BP control. Special considerations, such as comorbid mental health conditions and individualized treatment plans, are also addressed. NPs play a pivotal role in improving outcomes by fostering patient engagement and adherence. By embracing this holistic approach, NPs are poised to enhance the quality of care and well-being of patients with CKD and HTN.
(Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
References: Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2023. 2023. www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html .
Pugh D, Gallacher PJ, Dhaun N. Management of hypertension in chronic kidney disease. Drugs . 2019;79(4):365–379. doi:10.1007/s40265-019-1064-1. [Erratum in: Drugs . 2020;80(13):1381].
Bakris GL, Sorrentino MJ, eds. Hypertension: A Companion to Braunwald's Heart Disease . 3rd ed. Elsevier; 2018.
Sanidas E, Papadopoulos D, Chatzis M, Velliou M, Barbetseas J. Renin angiotensin aldosterone system inhibitors in chronic kidney disease: a difficult equation. Am J Cardiovasc Drugs . 2021;21(6):619–627. doi:10.1007/s40256-021-00467-9.
Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: core curriculum 2019. Am J Kidney Dis . 2019;74(1):120–131.
Umeukeje EM, Washington JT, Nicholas SB. Etiopathogenesis of kidney disease in minority populations and an updated special focus on treatment in diabetes and hypertension. J Natl Med Assoc . 2022;114(3S2):S3–S9. doi:10.1016/j.jnma.2022.05.004.
USRDS. CKD in the general population. 2018.
Umeukeje EM, Young BA, Fullerton SM, et al. You are just now telling us about this? African American perspectives of testing for genetic susceptibility to kidney disease. J Am Soc Nephrol . 2019;30(4):526–530. doi:10.1681/ASN.2018111091.
Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int . 2021;99(3S):S1–S87. doi:10.1016/j.kint.2020.11.003.
Kim SM, Jung JY. Nutritional management in patients with chronic kidney disease. Korean J Intern Med . 2020;35(6):1279–1290. doi:10.3904/kjim.2020.408.
Friedman AN, Kaplan LM, le Roux CW, Schauer PR. Management of obesity in adults with CKD. J Am Soc Nephrol . 2021;32(4):777–790. doi:10.1681/ASN.2020101472.
Wong MM, Arcand J, Leung AA, Thout SR, Campbell NR, Webster J. The science of salt: a regularly updated systematic review of salt and health outcomes (December 2015-March 2016). J Clin Hypertens . 2017;19(3):322–332. doi:10.1111/jch.12970.
Kalantar-Zadeh K, Fouque D. Nutritional management of chronic kidney disease. N Engl J Med . 2017;377(18):1765–1776. doi:10.1056/NEJMra1700312.
Liyanage-Don N, Fung D, Phillips E, Kronish IM. Implementing home blood pressure monitoring into clinical practice. Curr Hypertens Rep . 2019;21(2):14. doi:10.1007/s11906-019-0916-0.
Hebert SA, Ibrahim HN. Hypertension management in patients with chronic kidney disease. Methodist Debakey Cardiovasc J . 2022;18(4):41–49. doi:10.14797/mdcvj.1119.
Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med . 2013;369(20):1892–1903. doi:10.1056/NEJMoa1303154. [Erratum in: N Engl J Med . 2014;158:A7255].
Agarwal R, Sinha AD, Cramer AE, et al. Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med . 2021;385(27):2507–2519. doi:10.1056/NEJMoa2110730.
Steuber TD, Lee J, Holloway A, Andrus MR. Nondihydropyridine calcium channel blockers for the treatment of proteinuria: a review of the literature. Ann Pharmacother . 2019;53(10):1050–1059. doi:10.1177/1060028019843644.
Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med . 2020;383(15):1436–1446. doi:10.1056/NEJMoa2024816.
Fitchett D, Butler J, van de Borne P, et al. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. Eur Heart J . 2018;39(5):363–370. doi:10.1093/eurheartj/ehx511.
Hamrahian SM, Falkner B. Hypertension in chronic kidney disease. Adv Exp Med Biol . 2017;956:307–325. doi:10.1007/5584_2016_84.
Bowling CB, O'Hare AM. Managing older adults with CKD: individualized versus disease-based approaches. Am J Kidney Dis . 2012;59(2):293–302. doi:10.1053/j.ajkd.2011.08.039.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int . 2024;105(4S):S117–S314.
Desta R, Blumrosen C, Laferriere HE, et al. Interventions incorporating therapeutic alliance to improve medication adherence in black patients with diabetes, hypertension and kidney disease: a systematic review. Patient Prefer Adherence . 2022;16:3095–3110. doi:10.2147/PPA.S371162.
Umeukeje EM, Merighi JR, Browne T, et al. Health care providers' support of patients' autonomy, phosphate medication adherence, race and gender in end stage renal disease. J Behav Med . 2016;39(6):1104–1114. doi:10.1007/s10865-016-9745-7.
Kini V, Ho PM. Interventions to improve medication adherence: a review. JAMA . 2018;320(23):2461–2473. doi:10.1001/jama.2018.19271.
Centers for Disease Control and Prevention. Chronic kidney disease surveillance system—United States. 2019. https://nccd.cdc.gov/ckd/ . Accessed November 12, 2023.
Umeukeje EM, Wild MG, Maripuri S, et al. Black Americans' perspectives of barriers and facilitators of community screening for kidney disease. Clin J Am Soc Nephrol . 2018;13(4):551–559. doi:10.2215/CJN.07580717.
Knoerl AM, Esper KW, Hasenau SM. Cultural sensitivity in patient health education. Nurs Clin North Am . 2011;46(3):335–340. doi:10.1016/j.cnur.2011.05.008.
Seifaei A, Askarinejad A, Bazrafshan Drissi H, et al. General anxiety disorder and primary hypertension: is there a link. J Nerv Ment Dis . 2023;211(7):525–529. doi:10.1097/NMD.0000000000001650.
Rantanen AT, Korkeila JJA, Löyttyniemi ES, Saxén UKM, Korhonen PE. Awareness of hypertension and depressive symptoms: a cross-sectional study in a primary care population. Scand J Prim Health Care . 2018;36(3):323–328. doi:10.1080/02813432.2018.1499588.
معلومات مُعتمدة: K23 DK114566 United States DK NIDDK NIH HHS; R03 DK129626 United States DK NIDDK NIH HHS; R01 DK133530 United States DK NIDDK NIH HHS
المشرفين على المادة: 0 (Antihypertensive Agents)
تواريخ الأحداث: Date Created: 20240625 Date Completed: 20240625 Latest Revision: 20240816
رمز التحديث: 20240816
DOI: 10.1097/01.NPR.0000000000000201
PMID: 38915144
قاعدة البيانات: MEDLINE
الوصف
تدمد:1538-8662
DOI:10.1097/01.NPR.0000000000000201